September 12, 2025Cancer ScienceOpen Access

Efficacy and Safety of T‐DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real‐World Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective multicenter study shows T-DXd improves overall survival in HER2-positive patients, highlighting its potential in challenging cases.

T-DXd achieved significant overall and intracranial efficacy in HER2-positive and low/zero breast cancer brain metastasis (BCBM), with promising survival metrics.
In HER2-positive patients, median progression-free survival was 11 months and overall survival was 46 months, demonstrating substantial treatment benefits.
This retrospective multicenter analysis included patients with various challenges like leptomeningeal disease, finding notable outcomes in different cohorts.
The study highlights adverse events including fatigue and appetite loss, while recognizing the importance of T-DXd in treating difficult cases.

Zhou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective multicenter study shows T-DXd improves overall survival in HER2-positive patients, highlighting its potential in challenging cases.